Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$86.75

0.54 (0.63%)

, IONS

Ionis Pharmaceuticals

$48.76

1.28 (2.70%)

18:24
10/07/18
10/07
18:24
10/07/18
18:24

Alnylam's Onpattro highly efficacious, safer than competitor, says Piper Jaffray

Piper Jaffray analyst Edward Tenthoff notes that Ionis Pharmaceuticals (IONS) announced FDA approval of TEGSEDI for treatment of hATTR polyneuropathy. The analyst also points out that the label includes a Black Box warning for thrombocytopenia and glomerulonephritis requiring every 2-week monitoring, and will be marketed by Ionis subsidiary Akcea (AKCA) with a Risk Evaluation and Mitigation Strategy. TEGSEDI is administered subcutaneously every week versus Alnylam's (ANLY) ONPATTRO intravenously every 3 weeks with steroids, he adds. Tenthoff believes that ONPATTRO appears safer and highly efficacious, and should win out. The analyst reiterates an Overweight rating and $160 price target on Alnylam shares.

ALNY

Alnylam

$86.75

0.54 (0.63%)

IONS

Ionis Pharmaceuticals

$48.76

1.28 (2.70%)

AKCA

Akcea Therapeutics

$31.85

1.24 (4.05%)

  • 23

    Oct

  • 27

    Nov

ALNY Alnylam
$86.75

0.54 (0.63%)

09/24/18
PIPR
09/24/18
NO CHANGE
Target $50
PIPR
Neutral
Ionis platelet issue now appears removed, says Piper Jaffray
The most important takeaway from Ionis Pharmaceuticals' APO(a)-LRx results this morning is that there appears to be no platelet issue associated with the LICA technology, Piper Jaffray analyst Tyler Van Buren tells investors in a research note titled "These LICA Results Are A Big Deal - Platelet Issue Now Appears Removed." As it relates to Tegsedi specifically, the analyst says that while the product's subcutaneous dosing provides a clear competitive advantage to Alnylam's (ALNY) Onpattro infusion regimen, many view it as being offset by the need for bi-weekly platelet monitoring. However, Van Buren now believes that the need for platelet monitoring is definitively removed with Ionis' LICA technology. He believes this morning's results provide significant long-term validation for Ionis' LICA technology platform. The analyst keeps a Neutral rating on Ionis Pharmaceuticals with a $50 price target.
09/27/18
PIPR
09/27/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam weakness on safety concerns a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff attributes the initial weakness today in shares of Alnylam Pharmaceuticals to safety concerns from the interim Phase III givosiran data in acute hepatic porphyrias. Safety was consistent with prior Phase I data showing no additional deaths or cases of pancreatitis, five serious adverse events were due to underlying disease and one discontinuation for liver transaminase elevation resolved, Tenthoff tells investors in a research note. The analyst says he's a buyer of Alnylam due to the unmet medical need in acute hepatic porphyrias. Tenthoff reiterates an Overweight rating on Alnylam with a $160 price target. The stock is down 1%, or $1.12, to $90.21 in early trading.
09/28/18
PIPR
09/28/18
NO CHANGE
Target $160
PIPR
Overweight
Piper says Alnylam making transition to commercial play on orphan diseases
After Alnylam announced an NDA filing on Onpattro for hATTR Amyloidosis in Japan, Piper Jaffray analyst Edward Tenthoff said the company is transitioning toward being a commercial play on orphan diseases. The analyst, who forecasts 2018 Onpattro sales of $10.7M growing to $81M in 2019, keeps an Overweight and $160 price target on Alnylam shares.
10/01/18
CANT
10/01/18
INITIATION
Target $135
CANT
Overweight
Alnylam initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Alnylam Pharmaceuticals with an Overweight rating and $135 price target.
IONS Ionis Pharmaceuticals
$48.76

1.28 (2.70%)

08/28/18
STFL
08/28/18
NO CHANGE
STFL
Hold
CRL for Waylivra 'somewhat of a surprise,' says Stifel
Stifel analyst Paul Matteis said the complete response letter for Ionis Pharmaceuticals (IONS) and Akcea Therapeutics' (AKCA) Waylivra was "somewhat of a surprise" given the positive advisory committee decision, though he also noted that "safety was acutely in focus" during the committee meeting. The basis of the CRL is not yet known and Akcea was "close to the vest" on its nature, leading Matteis to remove Waylivra from his valuations for the two stocks. Doing that lowered his Akcea price target to $25 from $33 and cut his Ionis target to $45 from $47. However, he thinks the main investor question will be regarding read-through to Tegsedi and Matteis' assumption for its approval remains unchanged, he added. The analyst keeps Hold ratings on Ionis and Akcea shares, which are down 12.5% and 29%, respectively, in pre-market trading.
09/18/18
NEED
09/18/18
INITIATION
Target $45
NEED
Buy
Akcea Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Akcea Therapeutics (AKCA) with a Buy rating and a price target of $45, saying it is an "attractive" way for investors to leverage "decades of innovation" by the parent Ionis Pharma (IONS) through ownership of its most advanced-stage programs. The analyst cites the unfolding "breakthrough" in the approval of a new class of antisense drugs which "directly block protein synthesis in cells by binding to RNA". Messer adds that Akcea is positioned for near-term commercial opportunity for its Tegsedi and Waylivra programs.
10/03/18
MSCO
10/03/18
NO CHANGE
Target $45
MSCO
Equal Weight
Ionis most likely gets Tegsedi approval with black box, says Morgan Stanley
Morgan Stanley analyst David Lebowitz laid out three potential scenarios for the upcoming FDA approval decision about Ionis Pharmaceuticals' Tegsedi, which is scheduled to come on or before October 6. If the FDA were to issue a complete response letter, or CRL, and prevent on-time launch, Lebowitz sees greater than 20% downside for the shares, though he puts the probability of this occurring at 40%. If Tegsedi is approved with a black box safety warning, which he sees as the most likely scenario with odds he pegs at 45%, Lebowitz sees the stock trading up or down about 5%. If Tegsedi is approved with a "clean" label it would lead to a steeper ramp in revenue and Lebowitz sees 20% or more upside to the stock in this scenario, though he puts the odds at just 15%. He maintains an Equal Weight rating on Ionis shares ahead of the PDUFA with a $45 price target.
AKCA Akcea Therapeutics
$31.85

1.24 (4.05%)

08/28/18
HCWC
08/28/18
NO CHANGE
HCWC
Neutral
Ionis CRL for Waylivra raises questions on Tegsedi approval, says JPMorgan
Ionis Pharmaceuticals (IONS) announced last night that its subsidiary Akcea Therapeutics (AKCA) received a complete response letter for Waylivra from the FDA. JPMorgan analyst Jessica Fye says she had a chance to catch up with management but that they did not provide much in the way of details regarding the CRL. Given that Waylivra and Tegsedi are both generation 2.5 products and both have had platelet safety issues, the market will naturally question if the risk of a CRL also extends to Tegsedi, Fye tells investors in a research note. The analyst expects Ionis shares to reflect greater risk to approval for Tegsedi as well as Waylivra. She notes that Waylivra is worth $2 per share in her model for Ionis while Tegsedi contributes greater than $10 per share. The stock in premarket trading is down 12%, or $6.68, to $47.02. Fye keeps a Neutral rating on Ionis Pharmaceuticals.
08/28/18
RILY
08/28/18
NO CHANGE
Target $230
RILY
Buy
Ionis CRL positive for Alnylam's Onpattro, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar believes the complete response letter for Ionis Pharmaceuticals' (IONS) and Akcea Therapeutics' (AKCA) Waylivra is positive for Alnylam Pharmaceuticals' (ALNY) Onpattro. The analyst reiterates a Buy rating on Alnylam with a $230 price target.

TODAY'S FREE FLY STORIES

10:30
10/18/18
10/18
10:30
10/18/18
10:30
General news
EIA Natural Gas Storage Change for the week ending October 12 »

Gas Inventories 81 Bcf…

10:30
10/18/18
10/18
10:30
10/18/18
10:30
General news
EIA Natural Gas Storage Change for the week ending October 12 »

Gas Inventories 81 Bcf…

MU

Micron

$41.57

-0.79 (-1.87%)

10:30
10/18/18
10/18
10:30
10/18/18
10:30
Options
1.7K Micron Nov 47 - Dec 52.5 call spreads trade 68c »

1.7K Micron Nov 47 - Dec…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,101.22

-14.77 (-1.32%)

, GOOGL

Alphabet Class A

$1,111.60

-15.07 (-1.34%)

10:28
10/18/18
10/18
10:28
10/18/18
10:28
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

GOOG

Alphabet

$1,101.22

-14.77 (-1.32%)

GOOGL

Alphabet Class A

$1,111.60

-15.07 (-1.34%)

BJ

BJ's Wholesale

$23.62

-0.35 (-1.46%)

CMCSA

Comcast

$36.38

-0.01 (-0.03%)

TRI

Thomson Reuters

$47.07

0.25 (0.53%)

ATOM

Atomera

$4.55

-0.1 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

  • 03

    Mar

IBM

IBM

$131.93

-2.12 (-1.58%)

, GPS

Gap

$25.89

-1.24 (-4.57%)

10:28
10/18/18
10/18
10:28
10/18/18
10:28
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…

IBM

IBM

$131.93

-2.12 (-1.58%)

GPS

Gap

$25.89

-1.24 (-4.57%)

YUM

Yum! Brands

$90.34

-1.03 (-1.13%)

ENLK

EnLink Midstream Partners

$18.27

-0.08 (-0.44%)

WING

Wingstop

$72.38

-1.55 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 29

    Oct

  • 07

    Nov

  • 13

    Nov

  • 03

    Mar

NKE

Nike

$76.52

0.02 (0.03%)

, UAL

United Continental

$88.41

-0.09 (-0.10%)

10:28
10/18/18
10/18
10:28
10/18/18
10:28
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…

NKE

Nike

$76.52

0.02 (0.03%)

UAL

United Continental

$88.41

-0.09 (-0.10%)

GNRC

Generac

$57.53

1.23 (2.18%)

PTI

Proteostasis

$7.85

5.96 (315.34%)

SB

Safe Bulkers

$2.69

0.11 (4.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TEVA

Teva

$21.53

0.34 (1.60%)

, MYL

Mylan

$32.58

-0.45 (-1.36%)

10:25
10/18/18
10/18
10:25
10/18/18
10:25
Recommendations
Teva, Mylan, Amneal Pharmaceuticals, Novartis analyst commentary  »

Sandoz results…

TEVA

Teva

$21.53

0.34 (1.60%)

MYL

Mylan

$32.58

-0.45 (-1.36%)

AMRX

Amneal Pharmaceuticals

$18.66

0.17 (0.92%)

NVS

Novartis

$86.38

1.04 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 28

    Feb

ETP

Energy Transfer Partners

$21.75

-0.055 (-0.25%)

, ETE

Energy Transfer Equity

$17.00

-0.05 (-0.29%)

10:25
10/18/18
10/18
10:25
10/18/18
10:25
Conference/Events
Energy Transfer Partners to host special shareholder meeting »

Special shareholder…

ETP

Energy Transfer Partners

$21.75

-0.055 (-0.25%)

ETE

Energy Transfer Equity

$17.00

-0.05 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

AAPL

Apple

$218.70

-2.5 (-1.13%)

10:21
10/18/18
10/18
10:21
10/18/18
10:21
Periodicals
EU won't pursue action against Ireland over Apple tax bill, Independent says »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHAS

PhaseBio

$0.00

(0.00%)

10:21
10/18/18
10/18
10:21
10/18/18
10:21
Syndicate
PhaseBio opens at $5.00, IPO priced at $5.00 »

Citi, Cowen and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GE

General Electric

$12.21

0.015 (0.12%)

10:20
10/18/18
10/18
10:20
10/18/18
10:20
Options
Earnings hedge in GE »

Earnings hedge in GE. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
U.S. leading index rose 0.5% to 111.8 in September »

U.S. leading index rose…

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
Today's U.S. reports »

Today's U.S. reports…

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
Treasury Action: yields are loitering near highs »

Treasury Action: yields…

10:20
10/18/18
10/18
10:20
10/18/18
10:20
General news
FX Action: The dollar »

FX Action: The dollar was…

LGND

Ligand

$207.27

4.52 (2.23%)

, NVS

Novartis

$86.49

1.15 (1.35%)

10:18
10/18/18
10/18
10:18
10/18/18
10:18
Recommendations
Ligand, Novartis analyst commentary  »

Ligand current valuation…

LGND

Ligand

$207.27

4.52 (2.23%)

NVS

Novartis

$86.49

1.15 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 06

    Nov

  • 07

    Nov

PTE

PolarityTE

$13.78

-0.81 (-5.55%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Hot Stocks
Breaking Hot Stocks news story on PolarityTE »

PolarityTE trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$230.34

-4.3 (-1.83%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Downgrade
Thermo Fisher rating change  »

Follow-up: Thermo Fisher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

HAL

Halliburton

$38.78

-0.78 (-1.97%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Downgrade
Halliburton rating change  »

Follow-up: Halliburton…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$9.23

-0.39 (-4.05%)

10:17
10/18/18
10/18
10:17
10/18/18
10:17
Downgrade
Superior Energy rating change  »

Follow-up:Superior Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/18/18
10/18
10:16
10/18/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTE

PolarityTE

$13.78

-0.81 (-5.55%)

10:16
10/18/18
10/18
10:16
10/18/18
10:16
Hot Stocks
PolarityTE jumps 2% to $14.94 after Citron calls shares 'a zero' »

In a new research report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$71.72

-6.53 (-8.35%)

10:15
10/18/18
10/18
10:15
10/18/18
10:15
Recommendations
Activision Blizzard analyst commentary  »

Activision's CoD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
10/18/18
10/18
10:15
10/18/18
10:15
General news
Breaking General news story  »

Week of 10/12 EIA Natural…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.